Related references
Note: Only part of the references are listed.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
Maria-Victoria Mateos et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
R. A. Kyle et al.
LEUKEMIA (2010)
How I treat multiple myeloma in younger patients
A. Keith Stewart et al.
BLOOD (2009)
Bortezomib in the front-line treatment of multiple myeloma
Paul G. Richardson et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Herve Avet-Loiseau et al.
BLOOD (2007)
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma
Bart Barlogie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients
DR Carrasco et al.
CANCER CELL (2006)
Biologic sequelae of nuclear factor-κB blockade in multiple myeloma:: therapeutic applications
N Mitsiades et al.
BLOOD (2002)
NF-κB as a therapeutic target in multiple myeloma
T Hideshima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
A long-term study of prognosis in monoclonal gammopathy of undetermined significance
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma:: therapeutic applications
T Hideshima et al.
ONCOGENE (2001)
Share Paper
